Medication Management

Astellas is bringing forward a new treatment option for children impacted by neurogenic detrusor overactivity, a bladder dysfunction related to neurological impairment.

Imatinib mesylate tablets have a market value of roughly $324 million for the 12 months ended January 2021, according to IQVIA.

Thorazine had a market value of roughly $108.6 million for the 12 months ended January 2021, according to IQVIA.

The product is being recalled due to a market complaint received, stating that one bottle labeled as 30-count telmisartan tablets 20 mg incorrectly contained 30 tablets of 40-mg telmisartan tablets.

Cardizem had a market value of approximately $56.7 million for the 12 months ended January 2021, according to IQVIA.

A study from Avalere, funded by the Association for Accessible Medicines, found that in 2021, Medicare Part D plans placed generic prescription drugs on generic tiers 45% of the time, a decrease from 64% in 2016.

Biogen and Alkermes claim that Teva’s generic infringes three patents that protect Vumerity, which Alkermes licenses exclusively to Biogen.

The medication is an oral, next generation vascular endothelial growth factor tyrosine kinase inhibitor.